APLS Stock Price History and Quote Analysis: Insights for Investors

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own APLS shares is 383, representing 97.39% of the company's common stock.

ASSENAGON ASSET MANAGEMENT S.A., in the last quarter, reduced its stake in APLS by -5.66% restricting it's holding to 2.02 million shares of worth nearly $118.95M. MORGAN STANLEY also lessened -47.12% of the APLS shares from its portfolio, reducing its holding to 1.64 million shares of worth $96.26M. JENNISON ASSOCIATES LLC also shunned APLS shares holding by -1.08% last quarter which brought its holding to 3.24 million shares worth $190.48M.

As per its latest 13F filing, DEUTSCHE BANK AG\ increased its stake in APLS by 88.07% in the last quarter. The institutional holder raised its holding to 1.61 million shares having worth more than $94.74M. GEODE CAPITAL MANAGEMENT, LLC also added 3.63% more shares of APLS to its portfolio, raising its holding to 1.69 million shares of worth $99.35M. FIRST TRUST ADVISORS LP also increased its APLS shares holding by 332.58% which brought its holding to 406.48 thousand shares worth $23.89M.

The insider with the most stakes in APLS is Deschatelets Pascal , Chief Scientific Officer at the company. Additionally, APLS stock is highly held by director Machiels Alec and Chief Executive Officer Francois Cedric among others.

Company executives, directors, and other insiders own 14.28% percent of Apellis Pharmaceuticals, Inc.'s stock. Within the last six months, there have been 7 transaction(s) in which APLS insiders have sold stock, totaling 39.67K shares. Insiders that have sold shares include CHOPAS JAMES GEORGE, DUNLOP A. SINCLAIR, and DESCHATELETS PASCAL.

There have been 0 transaction(s) during the past 6-months in which Apellis Pharmaceuticals, Inc. insiders have bought stock, totalling 0 shares

Around 2.73M Apellis Pharmaceuticals, Inc. shares are held by insiders, which represents about 14.28% of APLS stock.

APLS Chief Scientific Officer, Deschatelets Pascal holds the largest portfolio of the company's shares. APLS shares owned by Deschatelets total nearly 1.12 million.

DEUTSCHE BANK AG\ is the largest institutional owner in APLS which holds 1.61 million shares worth $94.74M or 1.36% of the total APLS shares outstanding followed by GEODE CAPITAL MANAGEMENT, LLC with ownership of 1.69 million shares representing 1.42% of the APLS ownership. BOXER CAPITAL, LLC is the third largest stakeholder with 1.73 million shares or 1.45% of the ownership worth more than $101.45M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the APLS is concerned, it is a stock which is optionable.

Number of APLS shares short is 16.27M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 121.77M shares of APLS are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, APLS has 81.84M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for APLS is 9.32.